Palosuran (BioDeep_00000842022)
代谢物信息卡片
Palosuran
化学式: C25H30N4O2 (418.23686399999997)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=NC2=CC=CC=C2C(=C1)NC(=O)NCCN3CCC(CC3)(CC4=CC=CC=C4)O
InChI: InChI=1S/C25H30N4O2/c1-19-17-23(21-9-5-6-10-22(21)27-19)28-24(30)26-13-16-29-14-11-25(31,12-15-29)18-20-7-3-2-4-8-20/h2-10,17,31H,11-16,18H2,1H3,(H2,26,27,28,30)
描述信息
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Murat Olukman, Cenk Can, Deniz Coşkunsever, Yiğit Uyanikgil, Türker Çavuşoğlu, Eser Sözmen, Soner Duman, Fatma Gül Çelenk, Sibel Ülker. Urotensin receptor antagonist palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
2019 Oct; 28(10):1393-1401. doi:
10.17219/acem/104544. [PMID: 31518496] - Patricia N Sidharta, Paul L M van Giersbergen, Jasper Dingemanse. Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects.
Pharmacology.
2018; 102(5-6):339-346. doi:
10.1159/000492936. [PMID: 30384375] - Yavuz Pehlivan, Recep Dokuyucu, Tuncer Demir, Davut Sinan Kaplan, Ibrahim Koc, Mustafa Orkmez, Ibrahim Halil Turkbeyler, Ali Osman Ceribasi, Ediz Tutar, Seyithan Taysi, Bunyamin Kisacik, Ahmet Mesut Onat. Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.
Inflammation.
2014 Aug; 37(4):1280-8. doi:
10.1007/s10753-014-9855-8. [PMID: 24604341] - Ahmet Mesut Onat, Yavuz Pehlivan, Ibrahim Halil Turkbeyler, Tuncer Demir, Davut Sinan Kaplan, Ali Osman Ceribasi, Mustafa Orkmez, Ediz Tutar, Seyithan Taysi, Mehmet Sayarlioglu, Bunyamin Kisacik. Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension.
Inflammation.
2013 Apr; 36(2):405-12. doi:
10.1007/s10753-012-9559-x. [PMID: 23100033] - Maria Fleseriu, Beverly M K Biller, James W Findling, Mark E Molitch, David E Schteingart, Coleman Gross. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
The Journal of clinical endocrinology and metabolism.
2012 Jun; 97(6):2039-49. doi:
10.1210/jc.2011-3350. [PMID: 22466348] - Laurence Desrues, Thomas Lefebvre, Céline Lecointre, Marie-Thérèse Schouft, Jérôme Leprince, Vincent Compère, Fabrice Morin, François Proust, Pierrick Gandolfo, Marie-Christine Tonon, Hélène Castel. Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity.
PloS one.
2012; 7(5):e36319. doi:
10.1371/journal.pone.0036319. [PMID: 22563490] - Philip Tsoukas, Emilie Kane, Adel Giaid. Potential Clinical Implications of the Urotensin II Receptor Antagonists.
Frontiers in pharmacology.
2011; 2(?):38. doi:
10.3389/fphar.2011.00038. [PMID: 21811463] - Ludger Leifeld, Christoph Clemens, Jörg Heller, Jonel Trebicka, Tilman Sauerbruch, Ulrich Spengler. Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure.
Digestive diseases and sciences.
2010 May; 55(5):1458-64. doi:
10.1007/s10620-009-0875-4. [PMID: 19582578] - Liffert Vogt, Carlos Chiurchiu, Harbajan Chadha-Boreham, Parisa Danaietash, Jasper Dingemanse, Samy Hadjadj, Henry Krum, Gerjan Navis, Eric Neuhart, Aneliya I Parvanova, Piero Ruggenenti, Arend Jan Woittiez, Reuven Zimlichman, Giuseppe Remuzzi, Dick de Zeeuw. Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy.
Hypertension (Dallas, Tex. : 1979).
2010 May; 55(5):1206-9. doi:
10.1161/hypertensionaha.109.149559. [PMID: 20231521] - Catherine M Simpson, Joseph J Smolich, Lara S Shekerdemian, Daniel J Penny. Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome.
Pediatric research.
2010 Feb; 67(2):150-7. doi:
10.1203/pdr.0b013e3181c345ea. [PMID: 19809374] - Patricia N Sidharta, Paul L M van Giersbergen, Jasper Dingemanse. Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects.
Journal of clinical pharmacology.
2009 Oct; 49(10):1168-75. doi:
10.1177/0091270009341181. [PMID: 19625629] - Patricia N Sidharta, Klaus Rave, Lutz Heinemann, Eleonora Chiossi, Stephan Krähenbühl, Jasper Dingemanse. Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.
British journal of clinical pharmacology.
2009 Oct; 68(4):502-10. doi:
10.1111/j.1365-2125.2009.03480.x. [PMID: 19843053] - H C G Prosser, M E Forster, A M Richards, C J Pemberton. Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury.
Peptides.
2008 May; 29(5):770-7. doi:
10.1016/j.peptides.2007.08.013. [PMID: 17900760] - Markus Tölle, Markus van der Giet. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.
Peptides.
2008 May; 29(5):743-63. doi:
10.1016/j.peptides.2007.08.029. [PMID: 17935830] - Zhihua Jiang, Jennifer J Michal, David J Tobey, Zeping Wang, Michael D Macneil, Nancy S Magnuson. Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus.
International journal of biological sciences.
2008 Apr; 4(2):96-102. doi:
10.7150/ijbs.4.96. [PMID: 18463714] - Jonel Trebicka, Ludger Leifeld, Martin Hennenberg, Erwin Biecker, Andreas Eckhardt, Nicolas Fischer, Andrea Schulze Pröbsting, Christoph Clemens, Frank Lammert, Tilman Sauerbruch, Jörg Heller. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
Hepatology (Baltimore, Md.).
2008 Apr; 47(4):1264-76. doi:
10.1002/hep.22170. [PMID: 18318439] - Alessandro Cosenzi. Non peptidic urotensin II antagonists: perspectives for a new class of drugs.
Cardiovascular & hematological agents in medicinal chemistry.
2008 Apr; 6(2):80-91. doi:
10.2174/187152508783955024. [PMID: 18473773] - Fraser D Russell. Urotensin II in cardiovascular regulation.
Vascular health and risk management.
2008; 4(4):775-85. doi:
10.2147/vhrm.s1983. [PMID: 19065995] - John McDonald, Madura Batuwangala, David G Lambert. Role of urotensin II and its receptor in health and disease.
Journal of anesthesia.
2007; 21(3):378-89. doi:
10.1007/s00540-007-0524-z. [PMID: 17680191] - Patricia N Sidharta, Frank D Wagner, Holger Bohnemeier, Arvid Jungnik, Atef Halabi, Stephan Krähenbühl, Harbajan Chadha-Boreham, Jasper Dingemanse. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients.
Clinical pharmacology and therapeutics.
2006 Sep; 80(3):246-56. doi:
10.1016/j.clpt.2006.05.013. [PMID: 16952491] - Martine Clozel, Patrick Hess, Changbin Qiu, Shuang-Shuang Ding, Markus Rey. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats.
The Journal of pharmacology and experimental therapeutics.
2006 Mar; 316(3):1115-21. doi:
10.1124/jpet.105.094821. [PMID: 16267137] - Yu-Ping Peng, Yi-Hua Qiu, Bei-Bei Chao, Jian-Jun Wang. Effect of lesions of cerebellar fastigial nuclei on lymphocyte functions of rats.
Neuroscience research.
2005 Mar; 51(3):275-84. doi:
10.1016/j.neures.2004.11.010. [PMID: 15710491] - Martine Clozel, Christoph Binkert, Magdalena Birker-Robaczewska, Céline Boukhadra, Shuang-Shuang Ding, Walter Fischli, Patrick Hess, Boris Mathys, Keith Morrison, Celia Müller, Claus Müller, Oliver Nayler, Changbin Qiu, Markus Rey, Michael W Scherz, Jörg Velker, Thomas Weller, Jian-Fei Xi, Patrick Ziltener. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
The Journal of pharmacology and experimental therapeutics.
2004 Oct; 311(1):204-12. doi:
10.1124/jpet.104.068320. [PMID: 15146030]